Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study

被引：0

作者：

Makoto Naganuma

Shinya Sugimoto

Tomohiro Fukuda

Keiichi Mitsuyama

Taku Kobayashi

Naoki Yoshimura

Hidehisa Ohi

Shinji Tanaka

Akira Andoh

Naoki Ohmiya

Keiichiro Saigusa

Takayuki Yamamoto

Yuichi Morohoshi

Hitoshi Ichikawa

Katsuyoshi Matsuoka

Tadakazu Hisamatsu

Kenji Watanabe

Shinta Mizuno

Takayuki Abe

Yasuo Suzuki

Takanori Kanai

机构：

[1] Keio University School of Medicine,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[2] Kurume University School of Medicine,Division of Gastroenterology, Department of Medicine

[3] Kitasato University Kitasato Institute Hospital,Center for Advanced IBD Research and Treatment

[4] Tokyo Yamate Medical Center,Department of Internal Medicine, Division of IBD

[5] Imamura Hospital,Department of Gastroenterology

[6] Hiroshima University Hospital,Department of Endoscopy and Medicine

[7] Shiga University of Medical Science,Department of Medicine

[8] Fujita Health University School of Medicine,Department of Gastroenterology

[9] Tokyo Saiseikai Central Hospital,Department of Medicine

[10] Yokkaichi Hazu Medical Center,IBD Center

[11] Yokohama Municipal Citizen’s Hospital,Department of Medicine

[12] Tokai University Hachioji Hospital,Department of Gastroenterology

[13] Toho University Sakura Medical Center,Department of Gastroenterology

[14] Toho University Sakura Medical Center,Department of Internal Medicine

[15] Kyorin University School of Medicine,The Third Department of Internal Medicine

[16] Hyogo College of Medicine,Department of Intestinal Inflammation Research

[17] Keio University School of Medicine,Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical and Translational Research Center

[18] Toho University Sakura Medical Center,Inflammatory Bowel Disease Center

来源：

Journal of Gastroenterology | 2020年 / 55卷

关键词：

Ulcerative colitis; Indigo naturalis; Anti-TNFa treatment; Steroid dependent;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：169 / 180

页数：11

共 50 条

[21] Haematological abnormalities during treatment with Janus kinase inhibitors in patients with Ulcerative Colitis: a post hoc analysis
Loveikyte, R.
Voorneveld, P. W.
Dijkstra, G.
van der Meulen-de Jong, A. E.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1671 - I1671
[22] Aging is Associated With Constipation in Japanese Patients With Ulcerative Colitis: A Post Hoc Analysis
Yagi, Sen
Furukawa, Shinya
Miyake, Teruki
Yoshida, Osamu
Shiraishi, Kana
Tange, Kazuhiro
Hashimoto, Yu
Kitahata, Shogo
Ninomiya, Tomoyuki
Hanayama, Masakazu
Suzuki, Seiyuu
Shibata, Naozumi
Murakami, Hidehiro
Ohashi, Katsuhisa
Tomida, Hideomi
Yamamoto, Yasunori
Takeshita, Eiji
Ikeda, Yoshio
Hiasa, Yoichi
GERONTOLOGY AND GERIATRIC MEDICINE, 2023, 9
[23] Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study
Afzali, Anita
Dignass, Axel
Fischer, Monika
Sninsky, Charles
Armuzzi, Alessandro
Wu, Chun
Ahmad, Harris A.
Memaj, Arteid
Harris, Sarah
Canavan, James B.
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S513 - S514
[24] Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: A Post Hoc Analysis From True North
Khan, Nabeel
Irving, Peter
Blumenstein, Irina
Horst, Sara
Ahmad, Harris
Lawlor, Garrett
Hobbs, Vanessa
Jain, Anjali
Memaj, Arteid
Ananthakrishnan, Ashwin
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S25 - S25
[25] Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study
Hoffmann, Peter
Globig, Anna-Maria
Thomann, Anne K.
Grigorian, Maximilian
Krisam, Johannes
Hasselblatt, Peter
Reindl, Wolfgang
Gauss, Annika
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 13
[26] The clinical efficacy and safety of indigo naturalis in induction & maintenance therapy for moderate-to-severe ulcerative colitis: A single-centre prospective uncontrolled open-label study
Matsuno, Y.
Hirano, A.
Torisu, T.
Fuyuno, Y.
Okamoto, Y.
Shin, F.
Tomohiko, M.
Umeno, J.
Hirakawa, Y.
Esaki, M.
Kitazono, T.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S588 - S588
[27] Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program
Michael Chiorean
Marco Daperno
Charlie W. Lees
Gianluca Bonfanti
Dimitrios Soudis
Irene Modesto
J. Jasper Deuring
Roger A. Edwards
Advances in Therapy, 2023, 40 : 4440 - 4459
[28] Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program
Chiorean, Michael
Daperno, Marco
Lees, Charlie W. W.
Bonfanti, Gianluca
Soudis, Dimitrios
Modesto, Irene
Deuring, J. Jasper
Edwards, Roger A. A.
ADVANCES IN THERAPY, 2023, 40 (10) : 4440 - 4459
[29] Efficacy and safety of ozanimod in older patients with ulcerative colitis (UC): post hoc analysis of the True North study
Chandwe, Kanta
Bwakura-Dangarembizi, Mutsa
Amadi, Beatrice
Tawodzera, Gertrude
Murch, Simon
Hill, Susan
Playford, Ray
VanBuskirk, Kelley
Prendergast, Andrew
Kelly, Paul
GUT, 2023, 72 (SUPPL_2) : A107 - A107
[30] Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study
Attauabi, M.
Vind, I.
Pedersen, G.
Bendtsen, F.
Seidelin, J. Benedict
Burisch, J.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S425 - S426

← 1 2 3 4 5 →